
BioLife Solutions BLFS
$ 21.31
-0.33%
Quarterly report 2025-Q3
added 11-06-2025
BioLife Solutions Interest Expense 2011-2026 | BLFS
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense BioLife Solutions
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 497 K | 1.3 M | 662 K | 289 K | - | 5 K | 5 K | 190 K | 100 K | - | 177 K | 742 K | 733 K | 671 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.3 M | 5 K | 448 K |
Quarterly Interest Expense BioLife Solutions
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 284 K | 247 K | 103 K | - | 97 K | 146 K | 253 K | - | 235 K | 384 K | 394 K | - | 142 K | -22 K | 131 K | - | -7 K | - | - | - | 3 K | - | 1 K | - | 1 K | 1 K | 3 K | - | 1 K | 1 K | 1 K | - | 1.08 K | 105 K | 83.3 K | - | 33.3 K | - | - | - | - | - | - | - | - | - | 177 K | - | 186 K | 186 K | 186 K | - | 186 K | 184 K | 179 K | - | 172 K | 165 K | 161 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 394 K | -22 K | 126 K |
Interest Expense of other stocks in the Medical instruments industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
149 | - | - | $ 810 M | ||
|
iRhythm Technologies
IRTC
|
5.44 M | $ 126.93 | 3.74 % | $ 4.06 B | ||
|
Alcon
ALC
|
204 M | $ 76.13 | 0.46 % | $ 40.4 B | ||
|
Ekso Bionics Holdings
EKSO
|
-26 K | $ 10.93 | -0.55 % | $ 26.5 M | ||
|
The Cooper Companies
COO
|
-16.4 M | $ 64.3 | -0.19 % | $ 12.8 B | ||
|
Repro Med Systems
KRMD
|
9.91 K | $ 4.03 | 1.77 % | $ 186 M | ||
|
Microbot Medical
MBOT
|
2 K | $ 2.17 | -1.36 % | $ 99.4 M | ||
|
Milestone Scientific
MLSS
|
126 K | $ 0.32 | 1.15 % | $ 26.3 M | ||
|
Haemonetics Corporation
HAE
|
-9.75 M | $ 60.81 | 1.38 % | $ 3.06 B | ||
|
electroCore
ECOR
|
14.9 K | $ 6.07 | -1.7 % | $ 51.5 K | ||
|
ICU Medical
ICUI
|
93.3 M | $ 122.32 | -2.0 % | $ 3.01 B | ||
|
Envista Holdings Corporation
NVST
|
-2.3 M | $ 26.79 | - | $ 4.5 B | ||
|
Isoray
ISR
|
2 K | - | 0.03 % | $ 108 M | ||
|
Glaukos Corporation
GKOS
|
13.6 M | $ 121.88 | 0.18 % | $ 5.9 B | ||
|
STERIS plc
STE
|
8.4 M | $ 221.92 | 0.08 % | $ 21.9 B | ||
|
Teleflex Incorporated
TFX
|
57 M | $ 136.38 | -0.13 % | $ 6.09 B | ||
|
Masimo Corporation
MASI
|
300 K | $ 178.6 | -0.02 % | $ 9.52 B | ||
|
InfuSystem Holdings
INFU
|
1.4 M | $ 10.6 | 2.71 % | $ 219 M | ||
|
Merit Medical Systems
MMSI
|
-2.39 M | $ 67.27 | -1.91 % | $ 3.98 B | ||
|
Utah Medical Products
UTMD
|
-120 K | $ 67.07 | -0.15 % | $ 217 M | ||
|
West Pharmaceutical Services
WST
|
-1 M | $ 301.01 | -1.6 % | $ 21.8 B | ||
|
Pulse Biosciences
PLSE
|
-52 K | $ 22.39 | -2.74 % | $ 1.51 B | ||
|
DENTSPLY SIRONA
XRAY
|
24 M | $ 11.9 | -0.13 % | $ 2.37 B | ||
|
Retractable Technologies
RVP
|
227 K | $ 0.63 | -1.72 % | $ 18.9 M | ||
|
Pro-Dex
PDEX
|
533 K | $ 51.94 | -0.32 % | $ 171 M | ||
|
LeMaitre Vascular
LMAT
|
5.18 M | $ 115.31 | 1.64 % | $ 2.61 B | ||
|
Predictive Oncology
POAI
|
3 | - | - | $ 31.1 M | ||
|
STAAR Surgical Company
STAA
|
2.25 M | $ 26.2 | 2.06 % | $ 1.3 B | ||
|
Stereotaxis
STXS
|
2 K | $ 1.94 | 0.26 % | $ 176 M | ||
|
Baxter International
BAX
|
290 M | $ 18.46 | 1.68 % | $ 9.47 B | ||
|
ResMed
RMD
|
3.2 M | $ 222.96 | 1.47 % | $ 32.6 B | ||
|
AtriCure
ATRC
|
683 K | $ 29.06 | -0.75 % | $ 1.39 B | ||
|
Harvard Bioscience
HBIO
|
-2.66 M | $ 6.56 | -4.37 % | $ 291 M | ||
|
AngioDynamics
ANGO
|
4.94 M | $ 11.01 | -0.81 % | $ 450 M | ||
|
Becton, Dickinson and Company
BDX
|
613 M | $ 150.72 | -0.92 % | $ 43.4 B | ||
|
Nephros
NEPH
|
2 K | $ 2.99 | 4.3 % | $ 31.1 M | ||
|
OraSure Technologies
OSUR
|
229 K | $ 2.97 | -1.17 % | $ 218 M | ||
|
Repligen Corporation
RGEN
|
8.12 M | $ 118.39 | 0.67 % | $ 6.6 M |